Article PDF first page preview

First page of Efficacy of Neoadjuvant Hormone Therapy Combined with Radical Prostatectomy in Improving Oncological Outcomes for Patients with cT3 Prostate Cancer: A Systematic Review and Meta-Analysis

Introduction: Prostate cancer (PCa), especially at clinical stage T3 (cT3), leads to significant health issues and economic costs, highlighting the urgent need for improved treatment strategies. This systematic review and meta-analysis aimed to evaluate the efficacy of neoadjuvant hormone therapy (NHT) combined with radical prostatectomy (RP) in enhancing oncological outcomes for patients with cT3 PCa. Methods: We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science for studies published until May 17, 2025. Randomized controlled trials (RCTs) comparing RP alone versus RP with NHT in cT3 PCa patients were included. Primary outcomes were positive surgical margin (PSM) rates and prostate-specific antigen progression-free survival (PSA-PFS). Pooled risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI) were calculated using fixed- or random-effects models, depending on heterogeneity. Results: From 9,800 screened records, 10 RCTs were included in the meta-analysis. NHT combined with RP significantly reduced PSM rates (RR=0.75, 95% CI: 0.60–0.94, P=0.01), with improved results noted in patients who received 6 months or more of NHT (RR=0.75, P=0.01). Subgroup analysis revealed pronounced benefits in Asian populations (RR=0.47, P=0.001), whereas North American cohorts showed non-significant trends (RR=0.87, P=0.18). Subgroup analysis showed significant benefits for Asian populations (RR=0.47, P=0.001), while North American groups exhibited trends that were not statistically significant (RR=0.87, P=0.18). NHT combined with RP demonstrated a modest but significant improvement in PSA-PFS (MD=1.60 months, 95% CI: 0.47–2.73, P=0.006), albeit with moderate heterogeneity (I²=65%). Sensitivity analyses and publication bias assessments (Egger’s P=0.599; Begg’s P=0.655) supported result robustness. Conclusion: NHT in conjunction with RP significantly improves oncological outcomes, particularly regarding PSM and PSA-PFS. However, the long-term survival benefits are still unclear, indicating the need for further research.

Journal Section:
Systematic Review
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025